Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
The company received seven observations in the Form-483
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
Subscribe To Our Newsletter & Stay Updated
